Shionogi-Backed Apnimed Seeks to Raise $160 Million in US IPO

Apnimed Inc., a late-stage drug developer focused on sleep apnea, is seeking to raise as much as $160 million in a US initial public offering.

To respect copyright, we link to the source rather than republishing the full text. Read the complete article on Bloomberg.